Document text
Centers for Disease Control and Prevention
National Center for Emerging and Zoonotic Infectious Diseases
ACIP Dengue Vaccines Work Group
Wilbur Chen, MD, MSc
ACIP Member and Workgroup Chair
Advisory Committee on Immunization Practices
ACIP Meeting June 22, 2023
▪DENV -1, 2, 3, 4
•Lifelong DENV type -specific
immunity
•Short -term cross -immunity (~1 –2
years)
•A second dengue infection is the
most important risk factor for
severe dengue
▪Dengue is the most common
mosquito -borne virus globallyDengue Virus
Dengvaxia ™
and previous
dengue
infectionClinical trials found different outcomes after
Dengvaxia ™vaccination among children with and
without previous dengue infection.
•Children without previous dengue infection had a
higher risk for hospitalization and severe dengue if
they were vaccinated and then had a DENV infection.
•Children with previous dengue infection were
protected from hospitalization and severe dengue if
they were vaccinated with Dengvaxia ™.
Dengvaxia ™ACIP Recommendation June 2021
Three doses of Dengvaxia are indicated
for the prevention of dengue disease
caused by dengue virus serotypes 1, 2,
3, and 4 in people 9 –16 years old with:
•laboratory confirmation of previous
dengue virus infection
AND
•living in endemic areas.
Previous Presentations to ACIP on TAK -003
Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov2022 2023
•
••
•Takeda dengue
vaccine safety and
efficacy presentation
Workgroup summary
and interpretationDengue epidemiology
Review of Sanofi dengue
vaccine and ACIP
recommendation
Presentations Today
Introduction of policy questions for TAK -003
•Dr. Alfonso Hernandez, CDC, NCEZID, DVBD
Cost effectiveness analysis and health impacts of routine vaccination
with TAK -003 dengue vaccine in Puerto Rico
•Dr. Guido España , Notre Dame
Summary of two economic models for dengue vaccine TAK -003 use in
Puerto Rico
•Dr. RajReni Kaul, CDC
Partial evidence to recommendations framework for TAK -003
•Dr. Joshua Wong, CDC, NCEZID, DVBD
Future Presentations to ACIP on TAK -003
*Timeline subject to changeSep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov2022 2023
•
••
•
•
••
••
•
•Takeda dengue
vaccine safety and
efficacy presentation
Workgroup summary
and interpretationPolicy questions
Cost-effective (CE) analysis
(CDC/Notre Dame)
Comparison of CE models
Partial EtRDengue epidemiology
Review of Sanofi dengue
vaccine and ACIP
recommendation Full EtR*
Draft recommendation*
Vote*
ACIP Dengue Vaccines Work Group
ACIP Members
•Wilbur Chen (Chair)
•Kathy Poehling
•Beth Bell
•Veronica McNally
CDC Co -Leads
•Gabriela Paz -Bailey
•Laura Adams
Ex Officio Members
•Kaitlyn Morabito (NIH)
•Ralph LeBlanc (FDA)
•Ihid Carneiro Leao (FDA)
•Kirk Prutzman (FDA)•Srihari Seshadri (DOD)
•Liaison Representatives
•Elizabeth Barnett (AAP)
•Rob Schechter (AIM)
Consultants
•Edwin Asturias
•Robert Atmar
•Alan Barrett
•IrisCardona
•Anna Durbin
•Tony Marfin
•Kristen Pierce
•Anita ShetCDC Contributors
•Joshua Wong
•Nicole Medina
•Mimi Eckert
•Rachel Eidex
•Alfonso Hernandez
•Susan Hills
•Terri Hyde
•Mike McNeil
•Jorge Munoz
•Erin Staples
•Cindy Weinbaum
•Rita Helfand